The board of WntResearch has appointed Per Norlén as the company’s new CEO.
Per Norlén has solid experience from the life science industry in general and the development of cancer drugs in particular, states WntResearch.
I would also like to take this opportunity to thank Pernilla Sandwall, who has now decided to move on, for her very important contribution to the company’s development; she leaves the company in a much better condition than when she started.”
“WntResearch’s board is very happy to have been able to recruit a CEO at this level and we are convinced that the company and its very interesting drug candidate will be able to develop to its full potential under Per’s leadership. His primary focus will of course be to ensure, together with the employees at WntResearch, a professional implementation of the ongoing clinical phase 2 study and to build relationships with potential future collaboration partners among the pharmaceutical companies. I would also like to take this opportunity to thank Pernilla Sandwall, who has now decided to move on, for her very important contribution to the company’s development; she leaves the company in a much better condition than when she started,” says Christer Nordstedt, WntResearch’s chairman of the board.
He will take up the post on 1 March 2024.
Per Norlén
Per Norlén, MD, PhD, has more than 20 years of experience from various international leadership positions in the pharmaceutical industry, both from Big Pharma and the biotechnology sector. He comes most recently from the role of CEO of the Danish biotechnology company Evaxion Biotech, which is listed on the Nasdaq in New York. During the period 2015–2021, Per Norlén was CEO of Alligator Bioscience AB, a research company active in cancer that was listed on the Nasdaq Stockholm in 2016, where he was also medical director and development manager. He has also worked in various leading positions in drug development, including at AstraZeneca.
He trained as a doctor at Lund University, did his doctorate in preclinical pharmacology and then became a docent in clinical pharmacology. Har is also a specialist in clinical pharmacology. Per has a long-term and very successful experience in the clinical development of cancer drugs. He also has many years of experience in business development and has been responsible for several large cooperation agreements between biotech companies and Big Pharma.
Photo: Evaxion
